Psilocybin

In the realm of contemporary science and healthcare, there exists an increasingly fervent excitement centered around an unassuming fungus that has captivated the imagination of researchers, clinicians, and the curious alike. Psilocybin, the mystical compound found in magic mushrooms, has emerged...

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant depression (TRD), bipolar II disorder and PTSD is the...

It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. This Trade To Black Podcast, Shadd Dales, Anthony Varrell, and Benjamin A. Smith take a more granular look at Cresco Labs, Columbia Care, and the news about COMPASS...

With timelines for the submission of approval for MDMA-assisted therapy becoming more clear, COMPASS Pathways (NASDAQ: CMPS) has provided their own estimation on when psilocybin-assisted therapy may obtain regulatory approval. Today, the company prognosticated on when that may be,...

The quest to advance psychedelic medicine in Canada received a big boost today. The Minister of Mental Health and Addictions, Carolyn Bennett, announced an investment of nearly $3 million through the Canadian Institutes of Health Research. This funding will support three clinical...

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ: CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the...

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions. Huge news tonight coming out of Australia. The...

Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. Drug Enforcement Agency (DEA) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog being...

If I asked you to picture someone who uses mushrooms (psilocybin), you would not imagine Larry Campbell, a 74-year-old Canadian Senator who has been in politics for two decades. But, Campbell opened up about his use of mushrooms at the Catalyst Psychedelics Summit in Ontario.  Campbell says he...

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug...

The market opportunity for legal psychedelics is in the hundreds of billions of dollars, “Shark Tank” judge Kevin O’Leary told the inaugural Benzinga Psychedelics Capital Conference on Tuesday. Investors never get the opportunity to position themselves in a brand new sector,...

A resolution requesting that Hawaii forms a psilocybin working group to study the therapeutic potential of the substance was approved by a state House committee, Marijuana Moment reported Friday. With a 5-0 vote in the House Health, Human Services and Homelessness Committee, the resolution...

In Hawaii, senators approved two identical measures to form a psilocybin working group, Marijuana Moment reported. The goal of the group would be to explore the therapeutic potential of the psychedelic, but the resolutions were amended and patient access will be contingent on federal approval...

Albert Labs, a British-Columbia based biotech company, announced Thursday that it closed its private placement and that its shares will begin trading on the Canadian Securities Exchange (CSE). Albert Labs will trade under the ticker symbol “ABRT.”  “The listing is the first...